University of Florida: Coronary Artery Disease trials

The registry lists 46 Coronary Artery Disease studies with University of Florida as lead sponsor. 7 are open to participants now and 26 have results posted.

Phase 2 1Phase 4 28No phase 17(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The Bridging Antiplatelet Therapy With Cangrelor 2 StudyRecruitingNCT07225842Phase 4
• Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)RecruitingNCT07025148Phase 4
• Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) StudyRecruitingNCT06821191Phase 4
• Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 InhibitorsRecruitingNCT06691191Phase 4
• Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary InterventionRecruitingNCT06228456Phase 4
• Tailoring Bleeding Reduction Approaches in Patients Undergoing PCIRecruitingNCT05681702Phase 4
• A Precision Medicine Approach to Identify Patients Undergoing Elective PCI at Risk of Peri-PCI Myocardial InfarctionRecruitingNCT05332262
• Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCICompletedNCT04668144Phase 4Results posted
• PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatmentCompletedNCT04634162Phase 4Results posted
• Ticagrelor With and Without Aspirin in Patients With Diabetes MellitusCompletedNCT04484259Phase 4Results posted
• Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCICompletedNCT04483583Phase 4Results posted
• Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery DiseaseCompletedNCT04006288Phase 4Results posted
• Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes MellitusCompletedNCT03774394Phase 4Results posted
• Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet TherapiesCompletedNCT03718429Phase 4Results posted
• Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation StudyCompletedNCT03489863Phase 4Results posted
• Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCICompletedNCT03437044Phase 4Results posted
• Peripheral Nerve Blocks for Above-the-knee AmputationsCompletedNCT03404180Phase 4Results posted
• Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery DiseaseCompletedNCT02539160Phase 4Results posted
• Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With MorphineCompletedNCT02403830Phase 4Results posted
• Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery DiseaseCompletedNCT02287909Phase 4Results posted
• Pharmacological Effects of Crushing Prasugrel in STEMI PatientsCompletedNCT02212028Phase 4Results posted
• In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated PatientsCompletedNCT02081443Not applicableResults posted
• A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:CompletedNCT02065479Phase 4Results posted
• Pharmacodynamic Evaluation of Switching From Prasugrel to TicagrelorCompletedNCT02016170Not applicableResults posted
• High Ticagrelor Loading Dose in STEMICompletedNCT01898442Phase 2Results posted
• Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in DiabetesCompletedNCT01852214Not applicableResults posted
• Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery DiseaseCompletedNCT01852175Not applicableResults posted
• Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet TherapyCompletedNCT01852162Not applicableResults posted
• Impact of Ticagrelor Re-load on Pharmacodynamic ProfilesCompletedNCT01731041Not applicableResults posted
• Aspirin Dosing in Diabetic PatientsCompletedNCT01201785Phase 4Results posted
• Prasugrel Re-load StrategiesCompletedNCT01201772Phase 4Results posted
• Study of the Arachidonate 5-Lipoxygenase Enzyme in Affecting the Risk for Coronary Heart DiseaseCompletedNCT00379808Not applicableResults posted
• EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial IschemiaCompletedNCT00187889Phase 4Results posted
• Genetic Testing of CYP2C19 in Prognostic Evaluation of Long-Term Major Adverse Cardiac and Vascular EventsActive, not recruitingNCT06855394
• Precision PCI RegistryActive, not recruitingNCT06143709
• Effect of Beet Juice Supplementation on Vascular and Inspiratory Muscle FunctionCompletedNCT04920799Not applicable
• Impact of Timing of PD Assessments on Measures of Platelet Reactivity in Patients Undergoing PCI Treated With CangrelorCompletedNCT04668495
• Implementation of CYP2C19 Genotyping to Guide Antiplatelet TherapyCompletedNCT02724319
• Edoxaban in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and ClopidogrelCompletedNCT02567461Phase 4
• Acute Vascular Response to Exercise in Women With Nonobstructive Coronary Artery DiseaseCompletedNCT02450318Not applicable
• Effect of Celecoxib on Markers of Vascular InflammationCompletedNCT00471341Phase 4
• Mechanism of Percutaneous Revascularization for Coronary Bifurcation DiseaseTerminatedNCT00429052
• Mindfulness-Based Stress Reduction and Myocardial IschemiaCompletedNCT00224835Not applicable
• QWISE - Study of Quinapril in Women With Chest Pain, Coronary Flow Reserve Limitations and Evidence of Myocardial IschemiaCompletedNCT00150826Phase 4
• INVEST: INternational VErapamil SR Trandolapril STudyCompletedNCT00133692Phase 4
• Social Support and Myocardial IschemiaCompletedNCT00005449